News

Pliaglis, a topical local anesthetic cream forms a pliable peel on the skin and is used on skin of adults to provide local analgesia for superficial aesthetic procedures,

The 2 day QP GMP passing facilitates the company to advance clinical development of its universal flu vaccine, M-001, in the EU. BiondVax will also collaborate with MonoSol

In the second quarter of 2012, Pfizer signed an option and merger agreement with NextWave and made a $20m option payment. At present Pfizer is executing its option

The Ligand will earn $2m milestone payment from Merck triggered by the initiation of Phase 2b/3 trial of dinaciclib for the treatment of patients with refractory chronic lymphocytic

Amicus is developing the investigational pharmacological chaperone Migalastat HCl under collaboration with GlaxoSmithKline. Study 012, designed to compare oral migalastat HCl to ERTs (Fabrazyme and Replagal), enrolled Fabry

CTP-499 is a potential treatment developed on the basis of DCE Platform for diabetic nephropathy, a form of chronic kidney disease. The composition of matter and pharmaceutical compositions

Alnylam’s ALN-TTR program includes ALN-TTR02 and ALN-TTRsc, a subcutaneously administered RNAi therapeutic. Alnylam chief executive officer John Maraganore said ALN-TTR program holds promise as a breakthrough therapy for

The EMA’s opinion if ratified by European Commission will enable Krystexxa to treat tophaceous gout patients, who have failed to normalise serum uric acid with xanthine oxidase inhibitors

Under the new pathway, the FDA is expected to allow developers of such drugs to conduct smaller, faster clinical trials and provide a "special medical use" label enabling